Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 581

1.

Reply to Cheng and Chuang.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 Jan 30. doi: 10.1093/cid/ciz081. [Epub ahead of print] No abstract available.

PMID:
30715199
2.

Efficacy of Human-simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-lactamase-producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model.

Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02382-18. doi: 10.1128/AAC.02382-18. [Epub ahead of print]

PMID:
30670411
3.

Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid.

Sutherland CA, Ozbal C, Nicolau DP.

Future Sci OA. 2018 Nov 15;5(1):FSO352. doi: 10.4155/fsoa-2018-0079. eCollection 2019 Jan.

4.

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.

Baker TM, Rogers W, Chavda KD, Westblade LF, Jenkins SG, Nicolau DP, Kreiswirth BN, Calfee DP, Satlin MJ.

Open Forum Infect Dis. 2018 Nov 19;5(12):ofy300. doi: 10.1093/ofid/ofy300. eCollection 2018 Dec.

5.
6.

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.

Almarzoky Abuhussain SS, Burak MA, Kohman KN, Jacknin G, Tart SB, Hobbs ALV, Adams DK, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

BMC Health Serv Res. 2018 Dec 4;18(1):932. doi: 10.1186/s12913-018-3751-0.

7.

Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Motos A, Kuti JL, Li Bassi G, Torres A, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01922-18. doi: 10.1128/AAC.01922-18. Print 2019 Feb.

PMID:
30509937
8.

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01040-18. doi: 10.1128/AAC.01040-18. Print 2019 Feb.

9.

Optimizing Antibiotic Administration for Pneumonia.

Motos A, Kidd JM, Nicolau DP.

Clin Chest Med. 2018 Dec;39(4):837-852. doi: 10.1016/j.ccm.2018.08.006. Review.

PMID:
30390753
10.

In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.

Almarzoky Abuhussain SS, Avery LM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01931-18. doi: 10.1128/AAC.01931-18. Print 2019 Jan.

PMID:
30373797
11.

Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.

Stein GE, Smith CL, Scharmen A, Kidd JM, Cooper C, Kuti J, Mitra S, Nicolau DP, Havlichek DH.

Surg Infect (Larchmt). 2019 Jan;20(1):55-61. doi: 10.1089/sur.2018.141. Epub 2018 Oct 23.

PMID:
30351195
12.

Corrigendum to Physical Compatibility of Meropenem and Vaborbactam with Select Intravenous Drugs During Simulated Y-site Administration [Clinical Therapeutics 40 (2018) 261-269].

Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL.

Clin Ther. 2018 Nov;40(11):1956. doi: 10.1016/j.clinthera.2018.09.013. Epub 2018 Oct 16. No abstract available.

PMID:
30336952
13.

Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education.

Almarzoky Abuhussain SS, Burak MA, Adams DK, Kohman KN, Tart SB, Hobbs ALV, Jacknin G, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

Open Forum Infect Dis. 2018 Oct 8;5(10):ofy206. doi: 10.1093/ofid/ofy206. eCollection 2018 Oct.

14.
15.

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2018 Sep 5. doi: 10.1093/cid/ciy749. [Epub ahead of print]

PMID:
30188976
16.

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Avery LM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00948-18. doi: 10.1128/AAC.00948-18. Print 2018 Nov.

PMID:
30181365
17.

Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.

Avery LM, Nicolau DP.

Int J Antimicrob Agents. 2018 Nov;52(5):688-691. doi: 10.1016/j.ijantimicag.2018.07.011. Epub 2018 Jul 22.

PMID:
30044946
18.

Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.

Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00506-18. doi: 10.1128/AAC.00506-18. Print 2018 Oct.

PMID:
30012755
19.

In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.

Monogue ML, Giovagnoli S, Bissantz C, Zampaloni C, Nicolau DP.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e02596-17. doi: 10.1128/AAC.02596-17. Print 2018 Sep.

PMID:
30012751
20.

Management of Pediatric Acute Hematogenous Osteomyelitis, Part II: A Focus on Methicillin-Resistant Staphylococcus aureus, Current and Emerging Therapies.

DeRonde KJ, Girotto JE, Nicolau DP.

Pharmacotherapy. 2018 Oct;38(10):1021-1037. doi: 10.1002/phar.2164. Epub 2018 Sep 4. Review.

PMID:
29989190
21.

Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.

Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01008-18. doi: 10.1128/AAC.01008-18. Print 2018 Sep.

PMID:
29967022
22.
23.
24.

Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Abdelraouf K, Utley L, Pucci MJ, Lister T, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00239-18. doi: 10.1128/AAC.00239-18. Print 2018 Jul.

25.

Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.

Asempa TE, Avery LM, Kidd JM, Kuti JL, Nicolau DP.

Am J Health Syst Pharm. 2018 Jul 15;75(14):1048-1056. doi: 10.2146/ajhp170839. Epub 2018 Jun 12.

PMID:
29895521
26.
27.

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model.

Abdelraouf K, Kim A, Krause KM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e01074-18. doi: 10.1128/AAC.01074-18. Print 2018 Aug.

28.

Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory.

Avery LM, Nicolau DP.

J Antimicrob Chemother. 2018 Aug 1;73(8):2264-2265. doi: 10.1093/jac/dky165. No abstract available.

PMID:
29746659
29.

Review of antimicrobial use and considerations in the elderly population.

Giarratano A, Green SE, Nicolau DP.

Clin Interv Aging. 2018 Apr 17;13:657-667. doi: 10.2147/CIA.S133640. eCollection 2018. Review.

30.

Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2018 Jul;91(3):294-297. doi: 10.1016/j.diagmicrobio.2018.01.020. Epub 2018 Feb 24.

PMID:
29661528
31.

Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.

Avery LM, Nicolau DP.

Expert Opin Investig Drugs. 2018 Apr;27(4):325-338. doi: 10.1080/13543784.2018.1460354. Epub 2018 Apr 10. Review.

PMID:
29611447
33.

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.

Rodriguez BA, Girotto JE, Nicolau DP.

Curr Pediatr Rev. 2018;14(2):97-109. doi: 10.2174/1573396314666180308150908. Review.

PMID:
29521242
34.

Optimizing skin and skin structure infection outcomes: considerations of cost of care.

Almarzoky Abuhussain SS, Goodlet KJ, Nailor MD, Nicolau DP.

Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3):235-244. doi: 10.1080/14737167.2018.1450142. Epub 2018 Mar 14. Review.

PMID:
29521147
35.

Subcutaneous cefazolin to reduce surgical site infections in a porcine model.

Dubrovsky G, Huynh N, Rouch JD, Koulakis JP, Nicolau DP, Sutherland CA, Putterman S, Dunn JCY.

J Surg Res. 2018 Apr;224:156-159. doi: 10.1016/j.jss.2017.11.056. Epub 2017 Dec 28.

PMID:
29506833
36.

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model.

Rico Caballero V, Almarzoky Abuhussain S, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02384-17. doi: 10.1128/AAC.02384-17. Print 2018 May.

37.

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.

Ghazi IM, Monogue ML, Tsuji M, Nicolau DP.

Pharmacology. 2018;101(5-6):278-284. doi: 10.1159/000487441. Epub 2018 Feb 22.

38.

Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.

Kidd JM, Kuti JL, Nicolau DP.

Expert Opin Pharmacother. 2018 Mar;19(4):397-408. doi: 10.1080/14656566.2018.1438408. Epub 2018 Feb 19. Review.

PMID:
29411661
39.

Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis.

Thabit AK, Monogue ML, Newman JV, Nicolau DP.

Int J Antimicrob Agents. 2018 May;51(5):727-732. doi: 10.1016/j.ijantimicag.2018.01.001. Epub 2018 Jan 8.

PMID:
29325762
40.

Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.

Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL.

Clin Ther. 2018 Feb;40(2):261-269. doi: 10.1016/j.clinthera.2017.12.007. Epub 2017 Dec 28. Erratum in: Clin Ther. 2018 Nov;40(11):1956.

PMID:
29290374
41.

Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.

Monogue ML, Almarzoky Abuhussain SS, Kuti JL, Nicolau DP.

Am J Health Syst Pharm. 2018 Jan 1;75(1):e36-e44. doi: 10.2146/ajhp170123.

PMID:
29273611
42.

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.

Monogue ML, Nicolau DP.

J Antimicrob Chemother. 2018 Apr 1;73(4):942-952. doi: 10.1093/jac/dkx483.

PMID:
29272436
43.

Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.

Stokem K, Zuckerman JB, Nicolau DP, Wungwattana M, Sears EH.

Respir Med Case Rep. 2017 Oct 28;23:8-9. doi: 10.1016/j.rmcr.2017.10.012. eCollection 2018.

44.

Clostridium difficile infection in the elderly: an update on management.

Asempa TE, Nicolau DP.

Clin Interv Aging. 2017 Oct 24;12:1799-1809. doi: 10.2147/CIA.S149089. eCollection 2017. Review.

45.

Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.

Thabit AK, Grupper M, Nicolau DP, Kuti JL.

J Pharm Pract. 2017 Dec;30(6):593-599. doi: 10.1177/0897190016684453. Epub 2016 Dec 21.

PMID:
29121839
46.

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.

Ghazi IM, Monogue ML, Tsuji M, Nicolau DP.

Int J Antimicrob Agents. 2018 Feb;51(2):206-212. doi: 10.1016/j.ijantimicag.2017.10.008. Epub 2017 Oct 27.

PMID:
29111435
47.

Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis.

Stainton SM, Monogue ML, Baummer-Carr A, Shepard AK, Nugent JF, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01880-17. doi: 10.1128/AAC.01880-17. Print 2018 Jan.

48.

Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles.

Grupper M, Nicolau DP, Aslanzadeh J, Tanner LK, Kuti JL.

J Clin Microbiol. 2017 Dec;55(12):3502-3512. doi: 10.1128/JCM.01241-17. Epub 2017 Oct 11.

49.

Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.

Rosa R, Rudin SD, Rojas LJ, Perez-Cardona A, Aragon L, Nicolau DP, Perez F, Hujer AM, Tekin A, Martinez O, Camargo JF, Bonomo RA, Abbo LM.

Clin Infect Dis. 2017 Aug 15;65(4):701-702. doi: 10.1093/cid/cix387. No abstract available.

50.

In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.

Goodlet KJ, Nicolau DP, Nailor MD.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01350-17. doi: 10.1128/AAC.01350-17. Print 2017 Dec.

Supplemental Content

Loading ...
Support Center